据悉，Revolution Medicines正在研发的泛RAS抑制剂RMC-6236(通用名为Daraxonrasib)是该公司拥有的 关键资产。Daraxonrasib这款前沿药物是一种口服靶向药、一种直接作用的RAS(ON)多选择性抑制剂， 用于治疗由RAS基因突变驱动的癌症。它直接作用于处于激活状态的RAS蛋白，阻断RAS与下游信号蛋 白的结合，从而抑制RAS信号通路的持续激活，减缓肿瘤细胞的生长和增殖。Daraxonrasib靶向常见的 致癌性RAS突变，包括G12X、G13X和Q61X突变，这些突变是胰腺导管腺癌(PDAC)、非小细胞肺癌 (NSCLC)和结直肠癌(CRC)等主要癌种的重要驱动因素。 智通财经APP获悉，艾伯维(ABBV.US)表示，该公司没有就收购专注于癌症领域的生物技术公司 Revolution Medicines(RVMD.US)进行谈判。受此消息影响，Revolution Medicines周三美股盘后跌逾 6%。 周三有报道称，艾伯维正在就收购Revolution Medicines进行"深入"谈判，该交易对后者这家尚未有产品 上市的公司估值可能超过200亿美元。受此消息 ...

We recently published 10 Stocks With Massive Gains; 5 at Record Highs. Revolution Medicines, Inc. (NASDAQ:RVMD) was one of the top performers on Wednesday. Revolution Medicines soared to a new all-time high on Wednesday, as investors took path from a report from The Wall Street Journal that it was set to be acquired by AbbVie that could value the former $20 billion, albeit the latter later in the day debunked the report. At intra-day trading, Revolution Medicines, Inc. (NASDAQ:RVMD) climbed to its highes ...

By Puyaan Singh Jan 7 (Reuters) - AbbVie on Wednesday denied it ​was in talks to buy ‌Revolution Medicines after the Wall Street Journal ‌reported the drugmaker was in advanced discussions to acquire the cancer-drug developer, citing people familiar with the ⁠matter. The company "is ‌not in discussions with Revolution Medicines," AbbVie said in ‍an emailed statement to Reuters. AbbVie shares were down 1.3% in extended trading, ​after closing 4% higher Revolution Medicines ‌said it does not comment on r ...

AbbVie is in advanced talks to buy cancer-drug developer Revolution Medicines , the Wall Street Journal reported on Wednesday, citing people familiar with the matter. ...

REDWOOD CITY, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 10:30 a.m. PT. To access the live webcast of the presentation, please ...

REDWOOD CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has been randomized in the RASolute 304 trial. RASolute 304 is a global, open-label, Phase 3 clinical trial evaluating the safety and efficacy of daraxonrasib, a RAS(ON) multi-selective inhibitor, in patients with resectable pancreatic ductal adenocarcinoma (PDAC) who have received surgery ...

Core Viewpoint - Revolution Medicines, Inc. has experienced a 27.9% increase in share price over the past month, outperforming the S&P 500, but faces challenges ahead of its next earnings release [1] Financial Performance - For Q3 2025, Revolution Medicines reported a loss of $1.61 per share, which was wider than the expected loss of $1.39, compared to a loss of $0.94 in the same quarter last year [2] - The company has not generated any revenue as it currently lacks approved products in its portfolio [2] Expense Analysis - Research and development expenses reached approximately $263 million, reflecting a 73% year-over-year increase, driven by higher clinical study costs and employee-related expenses [3] - General and administrative expenses were nearly $53 million, up 120% year-over-year, primarily due to increased employee-related costs [3] Guidance - The company maintained its full-year operating expenses guidance, expecting a range between $1.03 billion and $1.09 billion, which includes non-cash stock-based compensation expenses of $115-$130 million [4] Estimate Trends - There has been a downward trend in consensus estimates, with a shift of -5.4% over the past month [5] VGM Scores - Revolution Medicines holds a poor Growth Score of F, a Momentum Score of F, and a Value Score of F, placing it in the bottom 20% quintile for investment strategies [6] Outlook - The overall trend for estimates has been downward, with a Zacks Rank of 3 (Hold), indicating an expectation of in-line returns in the coming months [7] Industry Comparison - Revolution Medicines is part of the Zacks Medical - Biomedical and Genetics industry, where Biogen Inc. has seen a 16.1% gain over the past month [8] - Biogen reported revenues of $2.53 billion for the last quarter, a year-over-year increase of 2.8%, with an EPS of $4.81 compared to $4.08 a year ago [9]

Core Insights - The healthcare sector has outperformed all other sectors, including technology, since the beginning of September, with the State Street Health Care Select Sector SPDR ETF (XLV) rising by 13% during this period [2][5] - The Tema Oncology ETF (CANC) has experienced a significant increase of 28% since September and is up 41% year-to-date [2][5] Company Highlights - Revolution Medicines (RVMD) is the top holding in the Tema Oncology ETF, with a remarkable gain of 127% since August 11, attributed to its strong management and potential breakthrough in pancreatic cancer therapy [3][4] - Roche Holdings (RHHBY) is noted for its portfolio of cancer immunology drugs, trading at an attractive PE ratio of 15, and has a significant pipeline that could enhance its valuation, especially following a positive readout in a breast cancer trial [4][6] - Guardant Health (GH) specializes in diagnostics, particularly a liquid biopsy test for early cancer detection, which is particularly relevant for colorectal cancer, the fastest-growing cancer among young people in the US [6][7]

Core Viewpoint - Revolution Medicines (RVMD) is a clinical-stage oncology company valued at $15 billion, focusing on targeted therapies for RAS-addicted cancers stemming from mutations in RAS proteins [1]. Group 1: Stock Performance - RVMD has gained 96.53% since the Trend Seeker "Buy" signal was issued on September 2 [2]. - The stock recently traded at $78.47, reaching an all-time high of $79.07 on December 3 [4][6]. - RVMD shares are up nearly 60% over the past year, with a 30.78% increase in the last month alone [6][7]. Group 2: Technical Indicators - Barchart gives RVMD a 100% technical "Buy" opinion, indicating strong momentum [6][7]. - The stock has a Weighted Alpha of +109.79 and a Relative Strength Index (RSI) of 80.28, suggesting strong upward momentum [7]. - A technical support level is identified around $75.12 [7]. Group 3: Financial Projections - Revenue for Revolution Medicines is projected to increase by 903.48% next year [7]. - Earnings are estimated to decrease by 12.15% next year [7]. Group 4: Analyst Sentiment - Wall Street analysts are overwhelmingly bullish on RVMD, although sentiment varies across other platforms [6].

Sector Performance - Healthcare has outperformed all other sectors since the start of September, rising 13% [2] - The State Street Health Care Select Sector SPDR ETF (XLV) leads this performance, followed by technology at 9% and utilities at 5% [2] Fund Performance - The Tema Oncology ETF (CANC) has seen a significant increase of 28% since September and is up 41% year-to-date [2] Key Holdings in Oncology - Revolution Medicines (RVMD) is the top holding in the Tema Oncology ETF, with a remarkable gain of 127% since August 11 [3] - Roche Holdings (RHHBY) is highlighted for its attractive PE ratio of 15 and a strong pipeline of cancer immunology drugs, including a recent positive trial readout in breast cancer [4][5] - Guardant Health (GH) is noted for its liquid biopsy test that can detect cancer early, particularly colorectal cancer, which is rapidly increasing among young people in the US [5][6]